English
Segment disclosures
Company overviewPrecision BioSciences, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Food Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dtil:FoodSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 3806000 | USD | 20220315 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 2422000 | USD | 20220315 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 1606000 | USD | 20210318 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 1360000 | USD | 20200310 | Open filing evidence |
Operating Segments · Therapeutics Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dtil:TherapeuticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 111723000 | USD | 20220315 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 21863000 | USD | 20220315 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 20632000 | USD | 20210318 | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 9523000 | USD | 20200310 | Open filing evidence |
Food Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ck0001357874:FoodSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-03-31 | 643000 | USD | 20190429 | Open filing evidence |
| 2018-01-01 – 2018-03-31 | 81000 | USD | 20190429 | Open filing evidence |
Therapeutics Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ck0001357874:TherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-01-01 – 2019-03-31 | 4819000 | USD | 20190429 | Open filing evidence |
| 2018-01-01 – 2018-03-31 | 1447000 | USD | 20190429 | Open filing evidence |
Food Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dtil:FoodSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 1241000 | USD | 20211110 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 2829000 | USD | 20211110 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 918000 | USD | 20210812 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 1588000 | USD | 20210812 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 670000 | USD | 20210513 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 315000 | USD | 20211110 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 1898000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 58000 | USD | 20210812 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 1583000 | USD | 20210812 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1525000 | USD | 20210513 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 146000 | USD | 20201110 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 1359000 | USD | 20201110 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 570000 | USD | 20200813 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 1213000 | USD | 20200813 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 643000 | USD | 20200515 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 426000 | USD | 20191112 | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 934000 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 427000 | USD | 20190814 | Open filing evidence |
| 2018-01-01 – 2018-06-30 | 508000 | USD | 20190814 | Open filing evidence |
Food Segment · Operating Segments · Change
Statement Business Segments · Consolidation Items · Change In Accounting Estimate By Type
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dtil:FoodSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ChangeInAccountingEstimateByTypeAxis=dtil:ChangeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-07-01 – 2020-09-30 | 169000 | USD | 20201110 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 539000 | USD | 20201110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | -512000 | USD | 20200813 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 370000 | USD | 20200813 | Open filing evidence |
Operating Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dtil:OperatingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 0 | USD | 20261103 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 10838000 | USD | 20261103 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 10838000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 10838000 | USD | 20260505 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 34264000 | USD | 20260312 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 13000 | USD | 20261103 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 60000 | USD | 20261103 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 18000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 47000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 29000 | USD | 20260505 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 68696000 | USD | 20260312 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 576000 | USD | 20251103 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 68058000 | USD | 20251103 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 49898000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 67482000 | USD | 20250807 | Open filing evidence |
Therapeutics Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dtil:TherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 22795000 | USD | 20211110 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 106361000 | USD | 20211110 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 67887000 | USD | 20210812 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 83566000 | USD | 20210812 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 15679000 | USD | 20210513 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 7048000 | USD | 20211110 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 13541000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 1020000 | USD | 20210812 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 6493000 | USD | 20210812 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5473000 | USD | 20210513 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 4719000 | USD | 20201110 | Open filing evidence |
| 2019-01-01 – 2019-09-30 | 14357000 | USD | 20201110 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 4819000 | USD | 20200813 | Open filing evidence |
| 2019-01-01 – 2019-06-30 | 9638000 | USD | 20200813 | Open filing evidence |
| 2019-01-01 – 2019-03-31 | 4819000 | USD | 20200515 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 2115000 | USD | 20191112 | Open filing evidence |
| 2018-01-01 – 2018-09-30 | 5009000 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 1447000 | USD | 20190814 | Open filing evidence |
| 2018-01-01 – 2018-06-30 | 2894000 | USD | 20190814 | Open filing evidence |
Therapeutics Segment · Operating Segments · Change
Statement Business Segments · Consolidation Items · Change In Accounting Estimate By Type
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dtil:TherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ChangeInAccountingEstimateByTypeAxis=dtil:ChangeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-07-01 – 2020-09-30 | 2329000 | USD | 20201110 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | -816000 | USD | 20201110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | -3799000 | USD | 20200813 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | -3145000 | USD | 20200813 | Open filing evidence |